Integrated BioTherapeutics Inc (IBT) is the 2009 Emerging Company of the Year in Maryland. IBT is a research-based company dedicated to development of vaccines and biotherapeutic molecules targeting emerging infectious agents. We are located in Gaithersburg, Maryland. Our primary areas of focus is on Ebola and Marburg viral hemorrhagic fevers and staph aureus. IBT is developing a panfilovirus vaccine under a contract with NIAID. In addition IBT is also testing an SEB vaccine in phase I trials sponsored by NIH. IBT has a close working arrangement with many of the United States government agencies including the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), National Cancer Institute (NCI), National Institute of Health (NIH), and the Department of Defense (DOD). IBT Bioservices is our contract R&D services business. IBT Bioservices is developing screening assays and disease models to identify antiviral and antibacterial compounds and therapeutics for client companies. In addition, we offer contract testing using the Mesoscale Discovery platform by MSD. You can learn more about IBT Bioservices at www.ibtbioservices.com.
Looking for a particular Integrated BioTherapeutics, Inc. employee's phone or email?
The Integrated BioTherapeutics, Inc. annual revenue was $9.3 million in 2026.
Emily Kough is the Associate Director of Assay Development and QA and QC Manager of Integrated BioTherapeutics, Inc..
3 people are employed at Integrated BioTherapeutics, Inc..
Integrated BioTherapeutics, Inc. is based in Rockville, Maryland.
The NAICS codes for Integrated BioTherapeutics, Inc. are [5417, 541714, 54171, 54, 541].
The SIC codes for Integrated BioTherapeutics, Inc. are [873, 87].